Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes

BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin‐9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Gencer, Baris, Koskinas, Konstantinos C., Räber, Lorenz, Karagiannis, Alexios, Nanchen, David, Auer, Reto, Carballo, David, Carballo, Sebastian, Klingenberg, Roland, Heg, Dik, Matter, Christian M., Lüscher, Thomas F., Rodondi, Nicolas, Mach, François, Windecker, Stephan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5721754/
https://ncbi.nlm.nih.gov/pubmed/29122809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006537
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados